In this trial, empagliflozin reduced the risk of a broad spectrum of HF outcomes with no heterogeneity observed among patients with or without HF at baseline, vol.75 ,
, J. Clin. Med, vol.2020
Heart failure with preserved ejection fraction: Pathophysiology, diagnosis and treatment, Eur. Heart J, vol.32, pp.670-679, 2011. ,
Heart failure with preserved ejection fraction: Uncertainties and dilemmas, Eur. J. Heart Fail, vol.17, pp.665-671, 2015. ,
, J. Clin. Med, vol.2020, p.1110
Heart failure with preserved ejection fraction: Mechanisms, clinical features, and therapies, Circ. Res, vol.115, pp.79-96, 2014. ,
Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: Insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute, Circulation, vol.119, pp.3070-3077, 2009. ,
Outcome of heart failure with preserved ejection fraction in a population-based study, N. Eng. J. Med, vol.355, pp.260-269, 2006. ,
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial, Lancet, vol.362, pp.777-781, 2003. ,
Irbesartan in patients with heart failure and preserved ejection fraction, N. Engl. J. Med, vol.359, pp.2456-2467, 2008. ,
The perindopril in elderly people with chronic heart failure (PEP-CHF) study, Eur. Heart J, vol.27, pp.2338-2345, 2006. ,
A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: Effects on exercise tolerance and arterial distensibility, Circ. Heart Fail, vol.3, pp.477-485, 2010. ,
Spironolactone for heart failure with preserved ejection fraction, N. Engl. J. Med, vol.370, pp.1383-1392, 2014. ,
Effects of digoxin on morbidity and mortality in diastolic heart failure: The ancillary digitalis investigation group trial, Circulation, vol.114, pp.397-403, 2006. ,
The Hong Kong diastolic heart failure study: A randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction, vol.94, pp.573-580, 2008. ,
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial, JAMA, vol.309, pp.1268-1277, 2013. ,
Clinical Phenotypes in Heart Failure with Preserved Ejection Fraction, J. Am. Heart Assoc, 2016. ,
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur. Heart J, vol.37, pp.2129-2200, 2016. ,
Heart failure with a normal ejection fraction: Is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation, vol.104, pp.779-782, 2001. ,
Heart failure with preserved ejection fraction: A systemic disorder?, Rev. Med. Interne, vol.33, pp.370-380, 2012. ,
Unfolding Discoveries in Heart Failure, N. Engl. J. Med, vol.2020, pp.679-682 ,
The pre-HFpEF stage: A new entity that requires proper phenotyping for better management, Eur. J. Prev. Cardiol, 2020. ,
ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J. Am. Coll. Cardiol, vol.62, pp.147-239, 2013. ,
, J. Clin. Med, vol.2020, p.1110
Atrial failure as a clinical entity: JACC review topic of the week, J. Am. Coll. Cardiol, vol.2020, pp.222-232 ,
Impaired left atrial function in heart failure with preserved ejection fraction, Eur. J. Heart Fail, vol.16, pp.1096-1103, 2014. ,
Association of CMR-measured LA function with heart failure development: Results from the MESA study, JACC Cardiovasc. Imaging, vol.7, pp.570-579, 2014. ,
Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction, JACC Heart Fail, vol.5, pp.565-574, 2017. ,
Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction, Circ. Heart Fail, vol.8, pp.295-303, 2015. ,
Reduced left atrial function on exercise in patients with heart failure and normal ejection fraction, vol.96, pp.1017-1023, 2010. ,
Influence of left atrial function on exercise capacity and left ventricular function in patients with heart failure and preserved ejection fraction, Circ. Cardiovasc. Imaging, vol.10, 2017. ,
Impaired left atrial strain predicts abnormal exercise haemodynamics in heart failure with preserved ejection fraction, Eur. J. Heart Fail, vol.21, pp.495-505, 2019. ,
Left atrial dysfunction relates to symptom onset in patients with heart failure and preserved left ventricular ejection fraction, Eur. Heart J. Cardiovasc. Imaging, vol.16, pp.62-67, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02282410
Left atrial function and mortality in patients with NSTEMI an MDCT study, JACC Cardiovasc. Imaging, vol.4, pp.1080-1087, 2011. ,
Left atrial booster pump function is an independent predictor of subsequent life-threatening ventricular arrhythmias in non-ischaemic cardiomyopathy, Eur. Heart J. Cardiovasc. Imaging, vol.17, pp.1153-1160, 2016. ,
Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction, Circ. Heart Fail, vol.9, 2016. ,
Atrial dyssynchrony syndrome: An overlooked phenomenon and a potential cause of "diastolic" heart failure, Eur. J. Heart Fail, vol.14, pp.248-258, 2012. ,
Permanent left atrial pacing therapy may improve symptoms in heart failure patients with preserved ejection fraction and atrial dyssynchrony: A pilot study prior to a national clinical research programme, Eur. J. Heart Fail, vol.15, pp.85-93, 2013. ,
Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: A report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry, Eur. Heart J, vol.39, pp.4277-4284, 2018. ,
Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy, Circulation, vol.141, pp.4-6, 2020. ,
Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction, Eur. J. Heart Fail, 2020. ,
, J. Clin. Med, vol.2020, p.1110
Diastolic dysfunction and heart failure with preserved ejection fraction, J. Am. Coll. Cardiol. Imaging, vol.12, pp.2098-2099, 2019. ,
Heart failure with preserved ejection fraction: From mechanisms to therapies, Eur. Heart J, vol.39, pp.2780-2792, 2018. ,
Biological phenotypes of heart failure with preserved ejection fraction, J. Am. Coll. Cardiol, vol.70, pp.2186-2200, 2017. ,
Right ventricular dysfunction in heart failure with preserved ejection fraction: A systematic review and meta-analysis, Eur. J. Heart Fail, vol.18, pp.1472-1487, 2016. ,
Right heart dysfunction and failure in heart failure with preserved ejection fraction: Mechanisms and management. Position Statement on behalf of the Heart Failure Association of the European Society of Cardiology, Eur. J. Heart Fail, vol.20, pp.16-37, 2018. ,
The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction, Eur. Heart J, vol.40, pp.3707-3717, 2019. ,
Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction, Circulation, vol.137, pp.1796-1810, 2018. ,
Impaired pulmonary diffusion in heart failure with preserved ejection fraction, JACC Heart Fail, vol.4, pp.490-498, 2016. ,
Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction, JACC Heart Fail, vol.4, pp.490-498, 2016. ,
Signaling molecules in nonfamiliar pulmonary hypertension, N. Eng. J. Med, vol.348, pp.500-509, 2003. ,
Pulmonary hypertension in heart failure with preserved ejection fraction: A plea for proper phenotyping and further research, Eur. Heart J, vol.38, pp.2869-2873, 2017. ,
ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the, Endorsed by Association for European Pediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Trasplantation (ISHLT), vol.37, pp.67-119, 2015. ,
Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre-vs. post-capillary pulmonary hypertension, Eur. J. Cardiovasc. Imaging, vol.19, pp.425-432, 2018. ,
Pulmonary hypertension in heart failure. Epidemiology, right ventricular function and survival, Am. J. Respir Crit. Care Med, vol.192, pp.1234-1246, 2015. ,
RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction. Stratification of clinical phenotypes and outcomes, J. Am. Coll. Cardiol. Imaging, vol.10, pp.1211-1221, 2017. ,
Uselfulness of right ventricular to pulmonary circulation coupling as an indicator of risk for recurrent admissions in heart failure with preserved ejection fraction, Am. J. Cardiol, vol.124, pp.567-572, 2019. ,
Tricuspid regurgitation and mortality risk across left ventricular systolic function in acute heart failure, Circ. J, vol.79, pp.1526-1533, 2015. ,
Functional tricuspid regurgitation and recurrent admissions in patients with acute heart failure, Int. J. Cardiol, vol.291, pp.83-88, 2019. ,
Is tricuspid regurgitation a prognostic intervetional target or is it just an indicator of worst prognosis in heart failure patients?, Eur. Heart J, vol.40, pp.485-487, 2019. ,
Systemic consequences of pulmonary hypertension and right-sided heart failure, Circulation, vol.141, pp.678-693, 2020. ,
Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease, Eur. Heart J, vol.38, pp.2874-2878, 2017. ,
Modes of death in patients with heart failure and preserved ejection fraction, Int. J. Cardiol, vol.228, pp.422-426, 2017. ,
Abnormal right ventricular-pulmonary artery coupling in exercise in heart failure with preserved ejection fraction, Eur. Heart J, vol.37, pp.3293-3302, 2016. ,
Right ventricular function, right ventricular-pulmonary artery coupling, and heart failure risk 4 US communities. The Atherosclerosis Risk in Communities (ARIC) Study, JAMA Cardiol, vol.3, pp.939-948, 2018. ,
The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction, Eur. Heart J, vol.40, pp.3721-3730, 2019. ,
Deterioration in right ventricular structure and function over time in heart failure with preserved ejection fraction, Eur. Heart J, vol.40, pp.689-697, 2019. ,
Rapid right-sided deterioration in heart failure with preserved ejection fraction, Eur. Heart J, vol.40, pp.699-702, 2019. ,
Echocardiographic Findings in Patients with Mild to Moderate Chronic Kidney Disease without Symptomatic Heart Failure: A Population-Based Study, Cardiorenal Med, vol.9, pp.284-296, 2019. ,
Heart failure with preserved ejection fraction: A nephrologist-directed primer, Heart Fail. Rev, vol.22, pp.765-773, 2017. ,
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval, Int. J. Cardiol, vol.216, pp.46-51, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01760299
Heart failure drug treatment, Lancet, vol.393, pp.1034-1044, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02510811
, Cardiorenal Syndrome Revisited. Circulation, vol.138, pp.929-944, 2018.
The systemic nature of CKD, Nat. Rev. Nephrol, vol.13, pp.344-358, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01848408
Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease, Kidney Int, vol.85, pp.703-709, 2014. ,
The double challenge of resistant hypertension and chronic kidney disease, Lancet, vol.386, pp.1588-1598, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01758662
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction, N. Engl. J. Med, vol.381, 1995. ,
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy, N. Engl. J. Med, vol.380, pp.2295-2306, 2019. ,
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial, Diabetes Care, vol.41, pp.356-363, 2018. ,
Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline, Eur. J. Heart Fail, vol.21, pp.386-388, 2019. ,
Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey, JACC Heart Fail, vol.6, pp.273-285, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01847385
Cardiovascular outcome trials in patients with chronic kidney disease: Challenges associated with selection of patients and endpoints, Eur. Heart J, vol.40, pp.880-886, 2019. ,
Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction: A Cross-sectional Analysis From the ARIC Study, JAMA Netw ,
Symptoms characteristic of heart failure among CKD patients without diagnosed heart failure, J. Card. Fail, vol.17, pp.17-23, 2011. ,
A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation, J. Am. Coll. Cardiol, vol.62, pp.263-271, 2013. ,
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction, PLoS ONE, vol.13, 2018. ,
Inflammatory markers and incident heart failure risk in older adults: The Health ABC (Health, Aging, and Body Composition) study, J. Am. Coll. Cardiol, vol.55, pp.2129-2137, 2010. ,
Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction, Eur. J. Heart Fail, vol.17, pp.1006-1014, 2015. ,
Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction, J. Am. Coll. Cardiol, vol.72, pp.1081-1090, 2018. ,
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure, Circulation, vol.139, pp.1289-1299, 2019. ,
, Clonal Hematopoiesis of Indeterminate Potential). Circulation, vol.138, pp.666-668, 2018.
Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1?/NLRP3 Inflammasome, J. Am. Coll. Cardiol, vol.71, pp.875-886, 2018. ,
Culprit Mechanism(s) for Exercise Intolerance in Heart Failure With Normal Ejection Fraction, J. Am. Coll. Cardiol, vol.56, pp.864-866, 2010. ,
Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure with Preserved Ejection Fraction, Circulation, vol.141, pp.115-123, 2020. ,
Malignant" Left Ventricular Hypertrophy Identifies Subjects at High Risk for Progression to Asymptomatic Left Ventricular Dysfunction, Heart Failure, and Death: MESA (Multi-Ethnic Study of Atherosclerosis), J. Am. Heart Assoc, vol.7, 2018. ,
Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy, Circulation, vol.114, pp.216-225, 2006. ,
Race-Related Differences in Left Ventricular Structural and Functional Remodeling in Response to Increased Afterload: The ARIC Study, JACC Heart Fail, vol.5, pp.157-165, 2017. ,
Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction, Circulation, vol.124, pp.2491-2501, 2011. ,
Cellular Adhesion Molecules in Young Adulthood and Cardiac Function in Later Life: The CARDIA Study, J. Am. Coll. Cardiol, vol.2020 ,
HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells, Nat. Commun, vol.5, 2014. ,
Matrix, cytoskeleton, or myofilaments: Which one to blame for diastolic left ventricular dysfunction?, Prog. Cardiovasc. Dis, vol.47, pp.276-284, 2005. ,
Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: Evidence of M2 macrophage activation in disease pathogenesis, J. Card. Fail, vol.21, pp.167-177, 2015. ,
Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages, Cell Metab, vol.20, pp.614-625, 2014. ,
Dysregulation of IL-33/ST2 signaling and myocardial periarteriolar fibrosis, J. Mol. Cell. Cardiol, vol.128, pp.179-186, 2019. ,
Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure with Preserved Ejection Fraction, JACC Heart Fail, vol.4, pp.312-324, 2016. ,
Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin, JACC Basic Transl. Sci, vol.4, pp.575-591, 2019. ,
Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence, Biophys. J, vol.97, pp.825-834, 2009. ,
Myofilament protein carbonylation contributes to the contractile dysfunction in the infarcted LV region of mouse hearts, Cardiovasc. Res, vol.101, pp.108-119, 2014. ,
Nitrosative stress drives heart failure with preserved ejection fraction, Nature, vol.568, pp.351-356, 2019. ,
High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients with Heart Failure with Preserved Ejection Fraction: Insights from the Heart Failure Clinical Research Network, J. Am. Heart Assoc, vol.7, 2018. ,
Effect of Exercise Intensity and Duration on Cardiac Troponin Release, Circulation, vol.141, pp.83-85, 2020. ,
, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2020 by the authors. Licensee MDPI